Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8670, Japan.
Laboratory of Clinical Pharmacy & Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
Mol Pharm. 2022 Aug 1;19(8):2754-2764. doi: 10.1021/acs.molpharmaceut.2c00120. Epub 2022 Jun 29.
Blood-brain barrier (BBB)-permeable middle- or macromolecules (middle/macromolecules) have recently attracted significant attention as new drug delivery carriers into the human brain via receptor-mediated transcytosis (RMT). During the development process of such carriers, it is necessary to thoroughly evaluate their human BBB permeability levels. In such evaluations, our recently established human immortalized cell-based multicellular spheroidal BBB models (hiMCS-BBB models) have shown high potential. However, the specifics of those capabilities have yet to be elucidated. Therefore, in this study, we characterize the ability of the hiMCS-BBB models to evaluate RMT-mediated BBB penetration properties of middle/macromolecules. More specifically, we began by validating transferrin receptor (TfR)-mediated RMT functionalities using transferrin in the hiMCS-BBB models and then examined the BBB permeability levels of MEM189 antibodies (known BBB-permeable anti-TfR antibodies). The obtained results showed that, as with the case of transferrin, temperature-dependent uptake of MEM189 antibodies was observed in the hiMCS-BBB models, and the extent of that uptake increased in a time-dependent manner until reaching a plateau after around 2 h. To further expand the evaluation applicability of the models, we also examined the BBB permeability levels of the recently developed SLS cyclic peptide and observed that peptide uptake was also temperature-dependent. To summarize, our results show that the hiMCS-BBB models possess the ability to evaluate the RMT-mediated BBB-permeable properties of antibodies and peptides and thus have the potential to provide valuable tools for use in the exploration and identification of middle/macromolecules showing excellent BBB permeability levels, thereby contributing powerfully to the development of new drug delivery carriers for transporting drugs into the human brain.
血脑屏障(BBB)可渗透的中分子或大分子(中/大分子)作为通过受体介导的胞吞作用(RMT)进入人脑的新的药物递送载体,最近引起了极大的关注。在这些载体的开发过程中,有必要彻底评估它们对人类 BBB 的通透性水平。在这些评估中,我们最近建立的基于人永生化细胞的多细胞球体 BBB 模型(hiMCS-BBB 模型)显示出了巨大的潜力。然而,这些能力的具体细节尚待阐明。因此,在本研究中,我们对 hiMCS-BBB 模型评估 RMT 介导的 BBB 穿透中/大分子特性的能力进行了表征。更具体地说,我们首先使用转铁蛋白(TfR)在 hiMCS-BBB 模型中验证了 TfR 介导的 RMT 功能,然后检查了 MEM189 抗体(已知的 BBB 可渗透抗 TfR 抗体)的 BBB 通透性水平。获得的结果表明,与转铁蛋白的情况一样,MEM189 抗体在 hiMCS-BBB 模型中的摄取是温度依赖性的,摄取的程度随着时间的推移而增加,直到大约 2 小时后达到平台。为了进一步扩展模型的评估适用性,我们还检查了最近开发的 SLS 环肽的 BBB 通透性水平,并观察到肽的摄取也是温度依赖性的。总之,我们的结果表明,hiMCS-BBB 模型具有评估 RMT 介导的抗体和肽 BBB 通透性的能力,因此有可能提供有价值的工具,用于探索和识别具有出色 BBB 通透性的中/大分子,从而为开发将药物输送到人类大脑的新的药物递送载体提供有力支持。